Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erbitux Companion Test Approval Clears Path For Further Co-Development

This article was originally published in The Gray Sheet

Executive Summary

DakoCytomation expects reimbursement policies for ImClone's Erbitux colorectal cancer drug to guide adoption of companion diagnostic EGFR pharmDx

You may also be interested in...



ViroLogic Gets Molecular Cancer Test Platform With Aclara

ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1

ViroLogic Gets Molecular Cancer Test Platform With Aclara

ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1

Ventana Developing Companion Diagnostic For Novartis’ Gleevec Cancer Drug

Ventana Medical Systems expects to submit a premarket approval application by early next year for a c-kit diagnostic for use with Novartis' drug Gleevec (imatinib mesylate)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel